Comparing the current results to its competitors, Inspiremd Inc reported Revenue increase in the 2 quarter 2026 by 34.88 % year on year. The sales growth was above Inspiremd Inc 's competitors' average revenue growth of 11.92 %, achieved in the same quarter.
Inspiremd Inc 's Comment on Competition and Industry Peers
The company operates in the competitive market for carotid embolic prevention systems, specifically with its CGuard EPS and CGuard Prime products. Its competitors include Abbott Laboratories, Boston Scientific Corporation, Medtronic, Cordis Corporation, and Terumo Medical Corporation. These competitors generally possess advantages such as greater capital resources, larger customer bases, broader product lines, larger sales forces, more extensive marketing and management resources, larger research and development staffs, larger facilities, established reputations, strong customer relationships, and wider global distribution networks. The company asserts that its CGuard carotid stent system offers superior clinical outcomes with lower adverse event rates, presenting an opportunity to increase market share, particularly in emerging markets like the United States. Key competitive factors in this market include the strength of clinical evidence, patient outcomes, and adverse event rates.
August 5, 2024
In a milestone achievement for cardiovascular intervention, InspireMD has announced the successful completion of trial enrollment for the CREST-2 study, a pivotal clinical trial that evaluates the effectiveness and safety of carotid artery stenting (CAS) using the CGuard stent. This investigational device is noteworthy not only for its unique design, which incorporates a mesh that offers enhanced neuroprotection, but it is also the sole investigational carotid stent granted FDA approval for inclusion in the trial. Key Developments and Their Implications 1. Completion of CREST-2 Enrollment : InspireMD’s announcement regarding the completion of the CREST-2 study enrollment marks a significant step forward f...
March 26, 2024
A recent announcement by InspireMD, Inc. has unveiled the acceptance of an abstract for presentation at the Leipzig Interventional Course (LINC) 2024. The abstract highlights the one-year outcomes of the C-GUARDIANS Investigational Device Exemption (IDE) clinical trial, focusing on the CGuard Prime Carotid Stent System for treating carotid artery stenosis. The study showcases the potential of this innovative embolic prevention stent system for stroke prevention.InspireMD, a Nasdaq-listed medical device company based in Tel Aviv, Israel, has been developing the CGuard Embolic Prevention Stent (EPS) System in a bid to address stroke prevention. Carotid artery disease, characterized by the narrowing of the car...
Catheter Precision Inc is a medical device manufacturing company that specializes in the production of catheters and related components. The company follows a business-to-business (B2B) model, supplying its products to healthcare institutions, hospitals, and other medical device companies. With its focus on precision and quality, Catheter Precision Inc aims to provide innovative and reliable solutions for various medical procedures involving catheters.
Transmedics Group Inc operates on a business model focused on medical technology. They develop and commercialize portable systems to facilitate the transplantation of organs and tissues. Their innovative platforms provide organ preservation, transportation, and monitoring solutions, aiming to improve patient outcomes in organ transplantation procedures.
Teleflex Incorporated operates with a diversified business model centered on the design, development, manufacturing, and distribution of specialty medical devices across various medical fields, including critical care, surgical, and respiratory care. The company is committed to delivering innovative and high-quality medical technologies that enhance patient outcomes and improve procedural efficiency for healthcare professionals worldwide.
Stryker Corps business model focuses on innovation in medical technologies and devices, specializing in areas such as orthopedics, surgical equipment, and neurotechnology, to enhance patient care and improve outcomes in the healthcare industry.
Sources:
Inspiremd Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Inspiremd Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
